The New York Society of Security Analysts, a leading forum for the investment community, recently announced the presenter list for its 14th Annual Biotech and Specialty Pharma Conference. Executives from eight small-cap biotechnology companies are scheduled to present at the conference, to be held Tuesday, November 30, 2010 in New York. Presenting companies are: ADVENTRX Pharmaceuticals, Inc., Anika Therapeutics, Inc., Cyclacel Pharmaceuticals, Inc., DARA BioSciences, Inc., EpiCept Corporation, GenSpera, Inc., PolyMedix, Inc., Provectus Pharmaceuticals, Inc., Senesco, and SuperGen.
Company executives from ADVENTRX Pharmaceuticals, Cyclacel Pharmaceuticals, and EpiCept Corporation presented at the OneMedForum 2010 conference in San Francisco earlier this year and are scheduled to present at the upcoming OneMedForum San Francisco 2011 in January. OneMedForum conferences provide an opportunity for innovative life science companies to connect with investors. ADVENTRX is focused on developing and commercializing product candidates for the treatment of cancer. The company recently filed a New Drug Application with the FDA for its lead drug candidate, Exelbine. Cyclacel Pharmaceuticals is a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious diseases. The company currently has three medications in clinical development. EpiCept Corporation specializes in therapeutics for treating cancer and managing pain. Its lead product is Ceplene, which is approved for commercialization in Europe for the maintenance of remission and prevention of relapse in adult patients with acute myeloid leukemia (AML) who are in first remission.
For more information about the OneMedForum San Francisco 2011, to be held January 11-13, 2010, please visit http://www.onemedplace.com/forum.
